Abstract
Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Letters in Drug Design & Discovery
Title: Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient
Volume: 8 Issue: 2
Author(s): Leonard Amaral, Marta Martins and Miguel Viveiros
Affiliation:
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Abstract: Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Export Options
About this article
Cite this article as:
Amaral Leonard, Martins Marta and Viveiros Miguel, Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient, Letters in Drug Design & Discovery 2011; 8 (2) . https://dx.doi.org/10.2174/157018011794183860
DOI https://dx.doi.org/10.2174/157018011794183860 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renaissance in Antibiotic Discovery: Some Novel Approaches for Finding Drugs to Treat Bad Bugs
Current Medicinal Chemistry Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery Cytokines as a Therapeutic Target for Allergic Diseases: A Complex Picture
Current Pharmaceutical Design Current and Future Treatment Options in Idiopathic Pulmonary Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) Differential Enhancement of T Helper Type 1 (Th1)/Th2 Cytokine Production by Natural Killer T Cells Through Negative Feedback Regulation with Cytokine-conditioned Dendritic Cells
Current Immunology Reviews (Discontinued) Graphical Abstracts
Letters in Drug Design & Discovery Bacterial Efflux Pumps Involved in Multidrug Resistance and their Inhibitors: Rejuvinating the Antimicrobial Chemotherapy
Recent Patents on Anti-Infective Drug Discovery Developing Country Applications of Molecular Farming: Case Studies in South Africa and Argentina
Current Pharmaceutical Design Editorial: Comparison of Forgotten Surgical Techniques for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Drug-Induced Hypokalaemia
Current Drug Safety Vitamin D Intervention Trials in Critical Illness
Inflammation & Allergy - Drug Targets (Discontinued) The First Years of Linezolid Experience in Clinical Practice: A Balance and Future Implications
Anti-Infective Agents in Medicinal Chemistry Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews Editorial [Hot Topic:Nicotinamide Adenine Dinucleotide Biology and Disease(Executive Editor: W. Todd Penberthy)]
Current Pharmaceutical Design Effect of Pistacia atlantica on the Elimination of Helicobacter pylori and Improvement of Gastric Reflux in Patients with Chronic Cough: A Randomized Clinical Trial
Current Traditional Medicine Lipid-based Nanocarriers Loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges
Current Drug Targets Acetohydroxyacid Synthase: A Target for Antimicrobial Drug Discovery
Current Pharmaceutical Design Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design LC-MS/MS Assay for Quantification of a Novel Antitubercular Molecule S006-830: Pharmacokinetic and Plasma Protein Binding Studies in Rats
Current Pharmaceutical Analysis